Busulphan in blood and marrow transplantation: Dose, route, freguency and role of therapeutic drug monitoring

Current Clinical Pharmacology

Volumn 2, Issue 1, 2007, Pages 75-91

  Ellen Nath, Christa ^a   John Shaw, Peter ^a  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Bone marrow transplantation; Busulfan; Drug monitoring; Hepatic; Pharmacokinetics; Therapeutic drug monitoring; Veno occlusive disease

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; BUSULFAN; CARBAMAZEPINE; CLONAZEPAM; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; FLUDARABINE; LORAZEPAM; MELPHALAN; METHOTREXATE; METOCLOPRAMIDE; ONDANSETRON; PHENOBARBITAL; PHENYTOIN; THIOTEPA; THYMOCYTE ANTIBODY;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; BONE MARROW TOXICITY; BONE MARROW TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CATARACT; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FATALITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC MALIGNANCY; HEMORRHAGIC CYSTITIS; HUMAN; HYPERBILIRUBINEMIA; INTERSTITIAL PNEUMONIA; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LUNG TOXICITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; THALASSEMIA; TREATMENT OUTCOME; VIRUS PNEUMONIA; WHOLE BODY RADIATION;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE MARROW TRANSPLANTATION; BUSULFAN; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; INFUSIONS, INTRAVENOUS;

EID: 34248343471     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488407779422249     Document Type: Review

References (106)

1. Bhagwatwar HP, Phadungpojna S, Chow DS, Andersson BS. Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemother Pharmacol 1996; 37(5):401-408.
2. Schuler U, Schroer S, Kuhnle A, et al. Busulfan pharmacokinetics in bone marrow transplant patients: is drug monitoring warranted? Bone Marrow Transplant 1994; 14(5):759-765.
3. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002; 8(9):477-485.
4. Russell JA, Tran HT, Quinlan D, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8(9):468-476.
5. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89(8):3055-3060.
6. Baker KS, Bostrom B, DeFor T, Ramsay NK, Woods WG, Blazar BR. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia. Bone Marrow Transplant 2000; 26(6):607-614.
7. Chandy M, Balasubramanian P, Ramachandran SV, et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia - the role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 2005; 36(10):839-845.
8. Thall PF, Champlin RE, Andersson BS. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant 2004; 33(12):1191-1199.
9. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002; 8(9):493-500.
10. Elson LA, Galton DA, Till M. The action of chlorambucil (CB. 1348) and busulphan (myleran) on the haemopoietic organs of the rat. Br J Haematol 1958; 4(4):355-374.
11. Tutschka PJ, Santos GW. Bone marrow transplantation in the busulfan-treated rat. II. Effect of cyclophosphamide and antithymic serum on the presensitized state. Transplantation 1975; 20(2):116-122.
12. Tutschka PJ, Santos GW. Bone marrow transplantation in the busulfan-treated rat. I. Effect of cyclophosphamide and rabbit anti-rat thymocyte serum as immunosuppression. Transplantation 1975; 20(2):101-106.
13. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983; 309(22):1347-1353.
14. Bolanos-Meade J, Hartley E, Jones RJ. Long-Term Follow-up of Allogeneic Marrow Transplantation for Acute Myelogenous Leukemia after Treatment with Busulfan and Cyclophosphamide. Biol Blood Marrow Transplant 2006; 12(3):366-367.
15. Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85(11):3005-3020.
16. Blaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse [see comments]. Blood 1992; 79(10):2578-2582.
17. Clift RA, Buckner CD, Thomas ED, et al. Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. [see comment]. Blood 1994; 84(6):2036-2043.
18. Devergie A, Blaise D, Attal M, et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the French Society of Bone Marrow Graft (SFGM).[see comment]. Blood 1995; 85(8):2263-2268.
19. Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies. Transplant Proc 1994; 26(3):1831-1832.
20. Ferry C, Socie G. Busulfan-cyclophosphamide versus total body irradiation-cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: what have we learned? Exp Hematol 2003; 31(12):1182-1186.
21. Ringden O, Remberger M, Ruutu T, et al. Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group.(see comment]. Blood 1999; 93(7):2196-2101.
22. Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 2001; 98(13):3569-3574.
23. Bunin N, Aplenc R, Kamani N, Shaw K, Cnaan A, Simms S. Randomized trial of busulfan vs total body irradiation containing conditioning regimens for children with acute lymphoblastic leukemia: a Pediatric Blood and Marrow Transplant Consortium study. Bone Marrow Transplant 2003; 32(6):543-548.
24. Davies SM, Ramsay NK, Klein JP, et al. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. J Clin Oncol 2000; 18(2):340-347.
25. Blazar BR, Ramsay NK, Kersey JH, Krivit W, Arthur DC, Filipovich AH. Pretransplant conditioning with busulfan (Myleran) and cyclophosphamide for nonmalignant diseases. Assessment of engraftment following histocompatible allogeneic bone marrow transplantation. Transplantation 1985; 39(6):597-603.
26. Hobbs JR, Hugh-Jones K, Shaw PJ, Downie CJ, Williamson S. Engraftment rates related to busulphan and cyclophosphamide dosages for displacement bone marrow transplants in fifty children. Bone Marrow Transplant 1986; 1(2):201-208.
27. Shaw PJ, Hugh-Jones K, Hobbs JR, Downie CJ, Barnes R. Busulphan and cyclophosphamide cause little early toxicity during displacement bone marrow transplantation in fifty children. Bone Marrow Transplant 1986; 1(2):193-200.
28. Vassal G, Deroussent A, Challine D, et al. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992; 79(9):2475-2479.
29. Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994; 84(7):2357-2362.
30. Shaw PJ, Nath C, Berry A, Earl JW. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.[see comment]. Bone Marrow Transplant 2004; 34(3):197-205.
31. Shaw PJ, Bergin ME, Burgess MA, et al. Childhood acute myeloid leukemia: outcome in a single center using chemotherapy and consolidation with busulfan/cyclophosphamide for bone marrow transplantation. J Clin Oncol 1994; 12(10):2138-2145.
32. Hassan M, Oberg G, Bekassy AN, et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991; 28(2):130-134.
33. Vassal G, Koscielny S, Challine D, et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996; 37(3):247-253.
34. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25(1):55-61.
35. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20(4 Suppl 4):18-25.
36. Hassan M, Fasth A, Gerritsen B, et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996; 18(5):843-850.
37. Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002; 8(11):619-624.
38. Hassan M, Ljungman P, Bolme P, et al. Busulfan bioavailability. Blood 1994; 84(7):2144-2150.
39. Vassal G, Gouyette A, Hartmann O, Pico JL, Lemerle J. Pharmacokinetics of high-dose busulfan in children. Cancer Chemother Pharmacol 1989; 24(6):386-390.
40. Hassan M, Oberg G, Ehrsson H, et al. Pharmacokinetic and metabolic studies of high-dose busulphan in adults. Eur J Clin Pharmacol 1989; 36(5):525-530.
41. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant 1996; 17(2):225-230.
42. Tran H, Petropoulos D, Worth L, et al. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10(11):805-812.
43. Gibbs JP, Gooley T, Corneau B, et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999; 93(12):4436-4440.
44. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 1997; 57(24):5509-5516.
45. Bostrom B, Enockson K, Johnson A, Bruns A, Blazar B. Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplantation. Pediatr Transplant 2003; 7(Suppl 3):12-18.
46. Bolinger AM, Zangwill AB, Slattery JT, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000; 25(9):925-930.
47. Ehrsson H, Hassan M. Binding of busulfan to plasma proteins and blood cells. J Pharm Pharmacol 1984; 36(10):694-696.
48. Henner WD, Furlong EA, Flaherty MD, Shea TC, Peters WP. Measurement of busulfan in plasma by high-performance liquid chromatography. J Chromatogr 1987; 416(2):426-432.
49. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993; 33(3):181-186.
50. Coppell JA, Brown SA, Perry DJ. Veno-occlusive disease: cytokines, genetics, and haemostasis. Blood Rev 2003; 17(2):63-70.
51. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 1996; 24(9):1015-1019.
52. Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione S-transferases. Cancer Res 1996; 56(16):3678-3681.
53. Dirven HA, van Ommen B, van Bladeren PJ. Glutathione conjugation of alkylating cytostatic drugs with a nitrogen mustard group and the role of glutathione S-transferases. Chem Res Toxicol 1996; 9(2):351-360.
54. Damani LA, Houdi AA. Cytochrome P-450 and FAD-monooxygenase mediated S- and N-oxygenations. Drug Metabol Drug Interact 1988; 6(3-4):235-244.
55. Gurtoo HL, Hipkens JH, Sharma SD. Role of glutathione in the metabolism-dependent toxicity and chemotherapy of cyclophosphamide. Cancer Res 1981; 41(9 Pt 1):3584-3591.
56. Hassan M, Ljungman P, Ringden O, et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25(9):915-924.
57. DeLeve LD, Wang X. Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 2000; 60(3):143-154.
58. Sjoo F, Aschan J, Barkholt L, Hassan Z, Ringden O, Hassan M. N-acetyl-L-cysteine does not affect the pharmacokinetics or myelo-suppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation. Bone Marrow Transplant 2003; 32(4):349-354.
59. Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70(5):1382-1388.
60. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118(4):255-267.
61. Meresse V, Hartmann O, Vassal G, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10(2):135-141.
62. McCune JS, Gooley T, Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30(3):167-173.
63. Radich JP, Gooley T, Bensinger W, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003; 102(1):31-35.
64. Li CK, Yuen PM, Wong R, et al. Busulphan level and early mortality in thalassaemia patients after BMT. Bone Marrow Transplant 1999; 23(4):307-310.
65. Poonkuzhali B, Srivastava A, Quernin MH, et al. Pharmacokinetics of oral busulphan in children with beta thalassemia major undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 24(1):5-11.
66. Lucarelli G, Clift RA, Galimberti M, et al. Marrow transplantation for patients with thalassemia: results in class 3 patients. Blood 1996; 87(5):2082-2088.
67. Pawlowska AB, Blazar BR, Angelucci E, Baronciani D, Shu XO, Bostrom B. Relationship of plasma pharmacokinetics of high-dose oral busulfan to the outcome of allogeneic bone marrow transplantation in children with thalassemia. Bone Marrow Transplant 1997; 20(11):915-920.
68. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004; 104(5):1574-1577.
69. Poonkuzhali B, Lapoumeroulie C, Shaji R, Chandy, Krishnamoorthy R, Srivastava A. GSTM1 null genotype is associated with elevated GST expression in children with beta thalassemia major. Blood 2006; 100(11):216b.
70. Shaughnessy PJ, Bachier C, Alexander L, Bowen B, LeMaistre CF. Intravenous busulfan dosed four times daily or once daily as part of the standard BuCy preparative regimen for allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11 (Supplement 1):28.
71. Bouligand J, Boland I, Valteau-Couanet D, et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 2003; 32(10):979-986.
72. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics.[erratum appears in Bone Marrow Transplant 1996 Oct; 18(4):829]. Bone Marrow Transplant 1995; 16(1):31-42.
73. Poonkuzhali B, Chandy M, Srivastava A, Dennison D, Krishnamoorthy R. Glutathione S-transferase activity influences busulfan pharmacokinetics in patients with beta thalassemia major undergoing bone marrow transplantation. Drug Metab Dispos 2001; 29(3):264-267.
74. Andersson BS, Gajewski J, Donato M, et al. Allogeneic stem cell transplantation (BMT) for AML, and MDS following i.v. busulfan and cyclophosphamide (i.v. BuCy). Bone Marrow Transplant 2000; 25(Suppl 2):S35-S38.
75. Hassan M, Nilsson C, Hassan Z, et al. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning. Bone Marrow Transplant 2002; 30(12):833-841.
76. Zwaveling J, Bredius RG, Cremers SC, et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005; 35(1):17-23.
77. Shimoni A, Bielorai B, Toren A, et al. Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity. Exp Hematol 2003; 31(5):428-434.
78. Lee JH, Choi SJ, Lee JH, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005; 84(5):321-330.
79. Sobocinski KA, Thall PF, Bekele BN, et al. Matched Pairs Analysis of IV vs. PO Busulfan as a Conditioning Agent Prior to Transplantation. ASH Annual Meeting Abstracts 2004; 104(11):349.
80. Mamlouk K, Saracino G, Berryman RB, et al. Modification of the Bu/ Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoring. Bone Marrow Transplant 2005; 35(8):747-754.
81. Williams CB, Day SD, Reed MD, et al. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant 2004; 10(9):614-623.
82. Fernandez HF, Tran HT, Albrecht F, Lennon S, Caldera H, Goodman MS. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule to patients with advanced hematologic malignant disease undergoing stem cell transplantation. Biol Blood Marrow Transplant 2002; 8(9):486-492.
83. Benn H, Amin A, Susan H-C, et al. Once daily intravenous (IV) busulfan (Bu) containing preparative regimens for hematopoietic stem cell transplantation (HSCT): Low incidence of Hepatic Veno-Occlusive Disease (HVOD) and improved early survival in a single center's experience. Biol Blood Marrow Transplant 2005; 11 (Supplement 1):31.
84. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104(3):857-864.
85. Schuler US, Renner UD, Kroschinsky F, et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol 2001; 114(4):944-950.
86. Cremers S, Schoemaker R, Bredius R, et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol 2002; 53(4):386-389.
87. Nath CE, Earl JW, Stephen K, Shaw PJ. Intravenous busulphan given once a day. Bone Marrow Transplant 2005; 35(Supplement 2):S21.
88. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004; 33(10):979-987.
89. Krivoy N, Hoffer E, Tabak A, et al. Therapeutic monitoring of busulfan in pediatric bone marrow transplantation. Pediatr Hematol Oncol 2002; 19(1):31-37.
90. Tran HT, Madden T, Petropoulos D, et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies. Bone Marrow Transplant 2000; 26(5):463-470.
91. Lindley C, Shea T, McCune J, et al. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy. Anticancer Drugs 2004; 15(5):453-459.
92. Andersson BS, Madden T, Tran HT, et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study. Biol Blood Marrow Transplant 2000; 6(5A):548-554.
93. Dupuis LL, Najdova M, Saunders EF. Retrospective appraisal of busulfan dose adjustment in children. [erratum appears in Bone Marrow Transplant. 2003 Apr;31(8):729; PMID: 12692614].
94. Dupuis LL, Najdova M, Saunders EF. Bone Marrow Transplant 2000; 26(11):1143-1147.
95. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001; 28(11):1013-1018.
96. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001; 28(8):743-751.
97. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002; 100(4):1201-1207.
98. Bornhauser M, Storer B, Slattery JT, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102(3):820-826.
99. Jenke A, Freiberg-Richter J, Johne C, et al. Targeting once-daily intravenous busulfan in combination with fludarabine before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2005; 35(6):627-628.
100. Madden T, Nguyen J, Thapar N, et al. The Pharmacokinetics (PK) of Once Daily Intravenous (IV) Busulfan (Bu) as Part of Pretransplant Preparative Regimens; a Comparison to Q 6 Hourly Dosing. Blood 2006; 102:477a.
101. Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12(4):472-479.
102. Kangarloo SB, Naveed F, Andersson BS, Quinlan D, Russell JA. Individualized Once-Daily Dosing of Intravenous Busulfan: A Pharmacokinetic Study in Patients Undergoing Conditioning for Allogeneic Stem Cell Transplantation. ASH Annual Meeting Abstracts 2004; 104(11):98.
103. Balasubramanian P, Chandy M, Krishnamoorthy R, Srivastava A. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation. Bone Marrow Transplant 2001; 28(9):821-825.
104. Chattergoon DS, Saunders EF, Klein J, et al. An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children. Bone Marrow Transplant 1997; 20(5):347-354.
105. Bullock JM, Smith PF, Booker BM, et al. Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 2006; 28(1):62-66.
106. Jacobson P, Park JJ, DeFor TE, et al. Oral busulfan pharmacokinetics and engraftment in children with Hurler syndrome and other inherited metabolic storage diseases undergoing hematopoietic cell transplantation. Bone Marrow Transplant 2001; 27(8):855-861.